Abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

Abrdn Life Sciences Investors (NYSE:HQL) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 77,800 shares, an increase of 212.4% from the December 31st total of 24,900 shares. Based on an average daily volume of 93,900 shares, the days-to-cover ratio is presently 0.8 days.

Insider Buying and Selling

In other news, major shareholder Saba Capital Management, L.P. sold 11,674 shares of Abrdn Life Sciences Investors stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $14.12, for a total transaction of $164,836.88. Following the completion of the sale, the insider now owns 3,418,349 shares of the company’s stock, valued at approximately $48,267,087.88. This trade represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.06% of the stock is owned by company insiders.

Institutional Investors Weigh In On Abrdn Life Sciences Investors

A number of large investors have recently made changes to their positions in the business. Penserra Capital Management LLC bought a new stake in Abrdn Life Sciences Investors during the third quarter valued at about $11,702,000. Absolute Investment Advisers LLC purchased a new stake in Abrdn Life Sciences Investors during the fourth quarter valued at approximately $5,242,000. Needham Investment Management LLC raised its position in Abrdn Life Sciences Investors by 3.2% during the third quarter. Needham Investment Management LLC now owns 352,719 shares of the company’s stock valued at $5,319,000 after purchasing an additional 10,904 shares during the period. Cetera Investment Advisers raised its holdings in shares of Abrdn Life Sciences Investors by 6.9% in the second quarter. Cetera Investment Advisers now owns 156,384 shares of the company’s stock worth $2,216,000 after buying an additional 10,137 shares during the period. Finally, Janney Montgomery Scott LLC grew its stake in Abrdn Life Sciences Investors by 7.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 91,398 shares of the company’s stock worth $1,199,000 after purchasing an additional 6,200 shares in the last quarter. 32.21% of the stock is currently owned by institutional investors.

Abrdn Life Sciences Investors Stock Up 0.2 %

NYSE:HQL traded up $0.03 during trading on Thursday, reaching $14.16. The company’s stock had a trading volume of 98,994 shares, compared to its average volume of 114,221. The firm has a 50 day moving average of $13.75 and a 200-day moving average of $14.62. Abrdn Life Sciences Investors has a 12 month low of $12.76 and a 12 month high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Investors of record on Thursday, November 21st were issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 14.12%. This is a boost from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. The ex-dividend date was Thursday, November 21st.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.